Viridian enrolled 321 patients in its safety study and finished the primary study in April. That is the concrete operating detail in a filing otherwise dominated by a familiar biotech arithmetic problem: progress does not arrive on the same schedule as profits.
The headline revenue number looks lively. Revenue rose to $284,000 in the three months ended June 30, from $75,000 a year earlier, a 279% increase. The base is still small enough that a modest collaboration payment can make the percentage look like it drank three espressos.
The loss line is less decorative. Operating loss widened to $126.3 million, and net loss reached $127.1 million, despite a decline in total research and development spending from $86.6 million to $71.6 million.
Viridian attributes the R&D reduction largely to the timing and stage of its phase 3 trials, rather than to a broad retreat from development. The largest decrease came from its TED portfolio, where clinical-trial and manufacturing costs fell by $19.7 million.
The company described that shift this way:
"Direct costs related to the TED portfolio decreased by $19.7 million during the three months ended June 30, 2026 compared to the three months ended June 30, 2025, primarily driven by a decrease in clinical trial and manufacturing associated costs due to the timing and stage of our phase 3 clinical trials for veligrotug."
Viridian, Form 10-Q, filed August 6, 2026
So the lower R&D bill is not the same thing as a lower level of business exposure. It reflects where the trials sat during this three-month period. Other research programs added $12.2 million, and personnel-related R&D costs rose by $5.8 million.
Headcount is part of that explanation. Viridian said personnel-related costs increased as it added staff to support ongoing research and development:
"Personnel-related costs increased by $9.3 million during the six months ended June 30, 2026 compared to the six months ended June 30, 2025, primarily attributable to increased headcount to support our ongoing research and development efforts."
Viridian, Form 10-Q, filed August 6, 2026
The company is therefore showing two different clocks. Trial-related spending can fall when a program moves between stages, while the organization supporting the pipeline keeps getting larger. Stock compensation rose 56.6% year over year, reaching $17.0 million, adding another personnel-linked cost even as direct TED and FcRn spending declined.
There was also a $10.0 million milestone payment to AbbVie after the FDA approved veligrotug in June. Viridian’s balance-sheet cash position is not disclosed in the supplied figures, but the filing says its Hercules loan maturity date is October 1, 2026. That puts financing timing alongside clinical timing, without turning either into a forecast.
The unresolved point is simple: how much of this period’s lower R&D spend was calendar noise, and how much reflects a durable change in trial intensity? Viridian’s next report can put a number against that question by showing whether total R&D remains near the $71.6 million reported for these three months.
Viridian’s 10-Q reported $71.6 million of R&D expense for the three months ended June 30, 2026.